The Trendlines Group's Portfolio Company ElastiMed Announces Strategic Distribution Agreement with U.S. Medical Technology Company

- *This strategic distribution partnership enables access to ElastiMed's compression device for the treatment of venous and lymphatic conditions.*
- *This commercial agreement highlights Trendlines' portfolio strength and the attractiveness of its medical companies in the global market.*
- *The Group holds approximately 31% in Elastimed, founded and incubated by Trendlines.*

Misgav, Israel, 18 May 2026 — The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, today announced that its portfolio company ElastiMed Ltd. ("**ElastiMed**"), a commercial-stage medical device company, pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices, has entered into a strategic U.S. distribution agreement with a U.S. medical technology company. Under the agreement, the medical company will serve as ElastiMed's strategic U.S. distribution partner for its FDA-cleared MyoSleeve wearable compression device.

The strategic U.S. distribution agreement marks a major milestone in ElastiMed's U.S. commercial launch strategy, providing immediate access to a large, underserved patient population.

The partnership leverages the distributor's established knowledge base, infrastructure and reimbursement expertise in the U.S. market. The agreement includes minimum purchase commitments and support for ElastiMed's growth trajectory. Additionally, the deal validates ElastiMed's proprietary EAP technology platform and the clinical and commercial potential of MyoSleeve.

ElastiMed's MyoSleeve combines clinical-grade compression with comfort and connectivity in a breakthrough, low-profile and comfortable wearable device, intended to promote compliance and ensure optimal clinical outcomes for the treatment of venous and lymphatic conditions.

Trendlines' CEO Haim Brosh commented: "This agreement affirms the strength, quality, and commercial promise within the Trendlines' portfolio, and demonstrates further progress and maturity of our portfolio. We take pride in backing companies that drive innovation while delivering meaningful impact in healthcare."

About ElastiMed

ElastiMed Ltd. is an Israeli medical device company pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices. Founded in 2015, the company has developed MyoSleeve - an FDA-cleared wearable compression device for the treatment of venous and lymphatic conditions. MyoSleeve delivers active, programmable compression through a soft, portable sleeve, offering a fundamentally different approach to a market long dominated by stationary compression garments. ElastiMed is preparing to execute its commercial launch in the United States.

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

----

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore:

Kamal Samuel, Financial PR

kamal@financialpr.com.sg

Rishika Tiwari, Financial PR

rishika@financialpr.com.sg

Tel: +65.6438.2990